DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 4, 2019, by DBV Technologies S.A., a foreign private issuer, reports on a significant capital raising event. The filing details an Underwriting Agreement entered into on April 3, 2019, with Goldman Sachs & Co. LLC and Citigroup Global Markets Inc. for a global offering of ordinary shares.
Key Financial Metrics
The filing focuses on the terms of the equity offering rather than operational financial performance metrics such as revenue or profit.
- Offering Structure: A public offering of 1,664,892 ordinary shares (3,329,784 ADSs) in the U.S. and Canada, and a concurrent private placement of 3,552,500 ordinary shares in Europe.
- Offering Price: $6.75 per ADS (based on an exchange rate of $1.1233 = €1.00) for the public offering; €12.02 per ordinary share for the private placement.
- Net Proceeds: Expected to be $65.2 million (€58.0 million) after deducting underwriting commissions and estimated offering expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 782,608 additional ordinary shares (1,565,216 ADSs).
- Closing Date: Expected on April 8, 2019, subject to customary conditions.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this document pertains solely to the securities offering.
Material Changes
The primary material change is the dilution of existing shareholders due to the issuance of 5,217,392 new ordinary shares (plus potential over-allotment) and the influx of approximately $65.2 million in net cash proceeds. The filing references amendments to the Company's shelf registration statement on Form F-3 filed on April 1, 2019.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the expectation that the Offering will close on April 8, 2019. Management cautions that actual results may differ due to market risks and uncertainties, including the satisfaction of closing conditions. The document incorporates by reference the "Risk Factors" section of the Company's Annual Report on Form 20-F. No specific operational guidance or outlook regarding clinical trials or product development is provided in this specific filing.
Key Facts for Investor Verification
- Verify the final closing of the Offering on or around April 8, 2019, and the actual net proceeds received.
- Confirm whether the underwriters exercised the 30-day option to purchase additional shares.
- Review the Company's Form 20-F for detailed risk factors and current cash position to assess the impact of the new capital.
- Check subsequent filings for the use of proceeds, which are typically outlined in the prospectus supplement.